Odonate Therapeutics, Inc.
OTC: ODTC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kevin C. Tang
- Employees
- 137
- Headquarters
- New York City, United States
- IPO year
- 2017
- Market cap
- $8.0B
- Website
- https://www.odonate.com
Loading ODTC…
Loading profile data…Frequently asked questions about ODTC
What does Odonate Therapeutics, Inc. (ODTC) do?
Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patie...
Where does ODTC trade?
Odonate Therapeutics, Inc. (ODTC) trades on the Other OTC.
What sector is ODTC in?
Odonate Therapeutics, Inc. (ODTC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Odonate Therapeutics, Inc.?
Kevin C. Tang is the chief executive officer of Odonate Therapeutics, Inc. (ODTC).
Where is Odonate Therapeutics, Inc. headquartered?
Odonate Therapeutics, Inc. is headquartered in United States.
Does ODTC pay a dividend?
Odonate Therapeutics, Inc. (ODTC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ODTC go public?
Odonate Therapeutics, Inc. (ODTC) completed its initial public offering in 2017.